Related Experiment Videos
Immunotherapy in patients with systemic mycoses: a promising adjunct
13rd Department of Paediatrics, University of Thessaloniki, Hippokration Hospital, Konstantinoupoleos 49, GR-546 42 Thessaloniki, Greece.
Summary
Cytokines show promise in treating fungal infections, but more clinical data are needed. Specific cytokines may aid neutropenic patients and those with aspergillosis.
Area of Science:
- Immunology
- Mycology
- Infectious Diseases
Background:
- Haemopoietic, T(H)1, and T(H)2 cytokines modulate host defense against fungi.
- In vitro and animal studies suggest cytokines as potential adjunctive therapy for systemic mycoses (SM).
- Limited clinical data currently support routine cytokine use in all SM patients.
Purpose of the Study:
- To review the evidence for cytokine use in managing systemic mycoses.
- To identify potential applications of specific cytokines in patient subgroups.
- To highlight areas for future research in cytokine-antifungal synergy.
Main Methods:
- Review of in vitro and animal model studies on cytokine roles in fungal defense.
- Analysis of existing clinical data on cytokine therapy for systemic mycoses.
- Identification of potential therapeutic applications based on current evidence.
Main Results:
- Cytokines play a modulatory role in fungal host defense.
- Granulocyte-macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) show potential in neutropenic patients.
- Interferon-gamma (IFN-γ) may benefit aspergillosis in chronic granulomatous disease (CGD).
- Granulocyte colony-stimulating factor (G-CSF)-elicited white blood cell transfusions could be life-saving in refractory SM.
Conclusions:
- No adjunctive cytokine treatment is currently justified for routine use in all SM patients.
- Specific cytokines like GM-CSF, M-CSF, and IFN-γ have potential in targeted patient populations.
- Further research into cytokine-antifungal synergy is crucial for developing effective treatments for serious fungal infections.